Abstract

Dietary fat is discussed to be critical in the development of non-alcoholic fatty liver disease. Here, we assess the effect of exchanging dietary fat source from butterfat to extra virgin olive oil on the progression of an already existing diet-induced non-alcoholic fatty liver disease in mice. Female C57BL/6J mice were fed a liquid butterfat-, fructose- and cholesterol-rich diet (BFC, 25E% from butterfat) or control diet (C, 12%E from soybean oil) for 13 weeks. In week 9, fat sources of some BFC- and C-fed mice were switched either to 25E% or 12E% olive oil (OFC and CO). Glucose and insulin tolerance tests were performed, and markers of liver damage and glucose metabolism were assessed. After 6 weeks of feeding, BFC-fed mice had developed marked signs of insulin resistance, which progressed to week 12 being not affected by the exchange of fat sources. Liver damage was similar between BFC- and OFC-fed mice. Markers of lipid metabolism and lipid peroxidation in liver and of insulin signaling in liver and muscle were also similarly altered in BFC- and OFC-fed mice. Taken together, our data suggest that exchanging butterfat with extra virgin olive oil has no effect on the progression of non-alcoholic fatty liver disease and glucose tolerance in mice.

Highlights

  • Insulin resistance is acknowledged as one of the key risk factors in the development of several metabolic diseases, among them non-alcoholic fatty liver disease (NAFLD) [1, 2]

  • Exchanging butterfat with extra virgin olive oil for the last 5 weeks of the feeding experiment had no effect on the elevation of fasting glucose or area under the curve (AUC) of glucose tolerance test (GTT) and insulin tolerance test (ITT)

  • Despite the clear signs of impaired glucose tolerance found in both, the GTT and the ITT, expression of insulin receptor (Ir) and insulin receptor substrate 2 (Irs2) mRNA was similar between both groups in muscle and liver tissue

Read more

Summary

Introduction

Insulin resistance is acknowledged as one of the key risk factors in the development of several metabolic diseases, among them non-alcoholic fatty liver disease (NAFLD) [1, 2]. Results of epidemiological studies suggest that NAFLD affects ~25% of the general global population and, depending on the area of the world studied, ~55–68% of patients with type 2 diabetes, making NAFLD the most prevalent liver disease in the world [3, 4]. Studies suggest that NAFLD soon will be the leading cause of liver transplantation in the US [5] and annual direct medical costs associated with the disease are estimated to account to approximately $1,613 per patient in the US and €354 to €1,163 per patient in Europe [6]. There was no additional external funding received for this study

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call